NC
ESPR

nVerses Capital’s Esperion Therapeutics ESPR Stock Holding History

nVerses Capital’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.5K Buy
+19,453
New +$54.4K 0.09% 263
2026
Q1 		– Sell
-67,450
Closed -$250K – 396
2025
Q4 		$250K Buy
+67,450
New +$218K 0.56% 85

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

nVerses Capital's ESPR Position: Q2 2026 in Review

nVerses Capital opened a new position in Esperion Therapeutics (ESPR) in Q2 2026: 19,453 shares worth $61.5K. The stake represents 0.09% of the portfolio and ranks #263 among its holdings. This is a return to the name: nVerses Capital previously reported a position in ESPR as recently as Q4 2025.

nVerses Capital first reported a position in ESPR in Q4 2025 and has held it in 2 quarters since. The position peaked at $250K in Q4 2025. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • nVerses Capital held 19,453 shares of Esperion Therapeutics worth $61.5K as of Q2 2026.
  • Esperion Therapeutics was a new nVerses Capital position in Q2 2026.
  • Esperion Therapeutics made up 0.09% of nVerses Capital's portfolio in Q2 2026, its #263 holding.
  • nVerses Capital first reported a position in Esperion Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • nVerses Capital's Esperion Therapeutics position peaked at $250K in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.